• EBOS acquires SVS Veterinary Supplies, a leading NZ pet supplies distributor, for NZ$115M
• EBOS acquires remaining 10% stake in Transmedic, a Southeast Asian medical device distributor
• Equity raising of up to A$250M via placement and retail offer to fund acquisitions

EBOS Group Limited is raising up to A$250M (NZ$272M) via a fully underwritten placement and a non-underwritten retail offer to fund two bolt-on acquisitions. EBOS has acquired SVS Veterinary Supplies, a leading supplier of pet medicines and products in New Zealand, for upfront consideration of NZ$115M and an earn-out of up to NZ$10M. SVS is expected to generate revenue of NZ$280M (A$254M) and EBITDA of NZ$17M (A$15M) in the 12 months to 31 March 2025. EBOS has also acquired the remaining 10% stake in Transmedic, a Southeast Asian medical device distributor, for A$35M. The equity raising will provide further balance sheet capacity for additional growth opportunities. EBOS reiterates its FY25 EBITDA guidance of A$575M-A$600M, excluding any contribution from SVS. In combination with the equity raising, the acquisitions are expected to be low single-digit percentage EPS accretive in FY25 on a pro forma basis.

EBOS reiterates its guidance that it expects to generate underlying EBITDA of between A$575 million to A$600 million in FY25, prior to any contribution from SVS.